Episcopal conference

Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, May 2, 2024
Sale, American Academy, Episcopal conference, MDA, Research, Muscular Dystrophy Association, DMD, Conference, Therapy, DYN, DM1, G&A, Pharmaceutical industry

WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter of 2024 and recent business highlights.

Key Points: 
  • (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter of 2024 and recent business highlights.
  • Research and development (R&D) expenses: R&D expenses were $44.5 million for the quarter ended March 31, 2024, compared to $37.5 million for the quarter ended March 31, 2023.
  • General and administrative (G&A) expenses: G&A expenses were $24.6 million for the quarter ended March 31, 2024, compared to $7.9 million for the quarter ended March 31, 2023.
  • Net loss: Net loss for the quarter ended March 31, 2024 was $65.6 million, or $0.81 per basic and diluted share.

Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage

Retrieved on: 
Wednesday, May 1, 2024
Health, Consumer, Women, Genetics, Baby, Maternity, Clinical Trials, Biotechnology, Fetus, Nucleic acid thermodynamics, Gamma globulin, Episcopal conference, American College, NTRA, Laboratory, RHD (gene), Anemia, Risk, Pregnancy, Blood, Northwell Health, Quality, Genetic testing, Obstetrics, DNA, SNP, ACOG, ASHG, NIPT, Patient, Human genetics, Society, Physician, Antibody, Panorama, Dietary supplement

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test.
  • This comes at a critical time for the healthcare industry, helping physicians navigate patient care given nationwide shortages of Rho(D) immune globulin therapy (RhIg).
  • Natera’s test can be performed as early as nine weeks gestation and determines fetal RhD status from the blood of a pregnant patient, including complex pseudogene and RhD-CE-D hybrid variants.
  • The vast majority of other NIPT laboratories do not offer fetal RhD assessment, which makes it a key differentiator in addition to Natera’s core SNP-based technology.

Rigrodsky Law, P.A. and Rowley Law PLLC Announce a Class Action and Proposed Settlement for All Persons Who Held Fewer Than 1,000 Shares of Westell Technologies, Inc. Common Stock

Retrieved on: 
Monday, April 15, 2024
Westell, Agreement, Hearing, Compromise, Prejudice, CLASS, Judgement, Class, ARE, The Honourable, Counsel, Effective date, Transaction, ACTION, Episcopal conference, All, Settlement, Person, Plaintiff, Insurance

YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.

Key Points: 
  • YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.
  • If approved by the Court, the Settlement will resolve all claims in the Action against Defendants.
  • Class Members do not have to submit a claim form to receive a payment from the Settlement.
  • All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed to the Settlement Administrator or Plaintiff's Counsel.

Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Prudential Securities Litigation

Retrieved on: 
Monday, April 8, 2024
Class Action Lawsuit, Professional Services, Legal, COMMON, Class Action, Failure, Prejudice, Notice, Prudential, District court, Telephone, ALL, Class, Episcopal conference, THIS, Judgement, Lawsuit, Court, Hearing, INC

The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Prudential Securities Litigation:

Key Points: 
  • The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Prudential Securities Litigation:
    TO: ALL PERSONS AND ENTITIES WHO PURCHASED THE COMMON STOCK OF PRUDENTIAL FINANCIAL, INC.
  • BETWEEN JUNE 5, 2019 AND AUGUST 2, 2019, INCLUSIVE (“CLASS” OR “CLASS MEMBERS”)
    THIS NOTICE WAS AUTHORIZED BY THE COURT.
  • Also, if the Court requires or allows Class Members to participate in the Settlement Hearing by telephone or videoconference, the access information will be posted to the Settlement website, www.PrudentialSecuritiesSettlement.com .
  • IF YOU PURCHASED PRUDENTIAL COMMON STOCK BETWEEN JUNE 5, 2019 AND AUGUST 2, 2019, INCLUSIVE, YOUR RIGHTS ARE AFFECTED BY THE SETTLEMENT OF THIS LITIGATION.

Labaton Keller Sucharow Announces a Proposed Class Action Settlement for All Record Holders and Beneficial Owners of Sculptor Capital Management, Inc. Common Stock Whose Shares Rithm Capital Corp. Acquired at the Closing of the Merger

Retrieved on: 
Friday, April 5, 2024
Class Action Lawsuit, Professional Services, Legal, Vii, Agreement, Prejudice, Notice, Defendant, Class, Episcopal conference, CLASS, Judgement, ARE, Settlement, Plaintiff, Eligibility, Effective date, Hearing, Compromise, LP, Mergers and acquisitions

SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER CLASS ACTION, SETTLEMENT HEARING,

Key Points: 
  • SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER CLASS ACTION, SETTLEMENT HEARING,
    All record holders and beneficial owners of Sculptor Capital Management, Inc. (“Sculptor”) common stock whose shares Rithm Capital Corp. (“Rithm”) acquired at the closing of the Merger.1
    PLEASE READ THIS SUMMARY NOTICE CAREFULLY.
  • YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.
  • The proposed Settlement, if approved, will resolve all claims in the Action and result in the dismissal of the Action with prejudice.
  • Eligible Class Members do not have to submit a claim form to receive a payment from the Settlement.

Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights

Retrieved on: 
Wednesday, March 27, 2024
Biotechnology, Health, Clinical Trials, Research, Conference, TSX Venture Exchange, MSCL, Regeneration, CFO, G&A, Toronto Stock Exchange, Muscular dystrophy, Doctor of Philosophy, MD, Senior, MBA, GMP, IND, Bank statement, TSX, Regenerative medicine, Duchenne muscular dystrophy, Facioscapulohumeral muscular dystrophy, Investment, Chemistry, Toxicology, Therapy, AAK1, OTCQB, FDA, GLP, Animal, DMD, FSHD, Hand, Episcopal conference, Food, CPA, Pharmaceutical industry

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the year ended December 31, 2023.

Key Points: 
  • Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the year ended December 31, 2023.
  • Subsequent to the year end, on March 4, 2024, Satellos announced positive preclinical data presented at the Muscular Dystrophy Association Clinical and Scientific Conference.
  • Satellos also announced that SAT-3247 would be nominated as its lead development candidate with SAT-3153 becoming the backup development candidate.
  • Satellos’ audited financial statements for the year ended December 31, 2023, and the related management’s discussion and analysis (MD&A) will be available on SEDAR+ at www.sedarplus.ca .

Levi & Korsinsky, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of AppHarvest, Inc. Securities

Retrieved on: 
Monday, April 1, 2024
Claim, Appharvest, Net, Tax, District court, LLP, Pearl Street, Episcopal conference, APPH, Counsel, Settlement, Plaintiff, Action Replay, Hearing, The Honourable, Person

NEW YORK, April 1, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers of AppHarvest, Inc. securities (NASDAQ: APPH) and (NASDAQ: APPHW).

Key Points: 
  • NEW YORK, April 1, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers of AppHarvest, Inc. securities (NASDAQ: APPH) and (NASDAQ: APPHW).
  • SUMMARY NOTICE OF PENDENCY OF CLASS ACTION, PROPOSED CLASS ACTION SETTLEMENT, FINAL APPROVAL HEARING, AND MOTION FOR ATTORNEYS' FEES AND EXPENSES
    To:      All persons and entities that purchased or otherwise acquired securities of AppHarvest, Inc., during the period from February 1, 2021 and August 10, 2021, inclusive, and were injured thereby (the "Settlement Class").
  • You do NOT need to attend the Settlement Hearing to receive a distribution from the Net Settlement Fund.
  • IF YOU ARE A MEMBER OF THE SETTLEMENT CLASS, YOUR RIGHTS WILL BE AFFECTED BY THE PROPOSED SETTLEMENT AND YOU MAY BE ENTITLED TO A MONETARY PAYMENT.

BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, April 1, 2024
Neuroprotection, Research, Conference, Prejudice, Disease, SPA, ALS, Patient, Biomarker, Committee, Gene, MD, Biologics license application, Agency, Safety, Brainstorm, Poster, Therapy, Marketing, FDA, BLA, Episcopal conference, Food, Pharmaceutical industry

NEW YORK, April 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • NEW YORK, April 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2023 and provided a corporate update.
  • We continue to believe that, if approved, NurOwn has the potential to be a valuable treatment option for ALS patients in need.
  • Stacy Lindborg, Ph.D., co-CEO BrainStorm commented, "We are acutely aware of the challenges faced by those afflicted with ALS.
  • In October 2023, Brainstorm announced a strategic realignment to enable accelerated development of NurOwn for the treatment of ALS.

Monteverde & Associates PC and Kahn Swick & Foti LLC Announce Proposed Class Action Settlement on Behalf of All Owners of Harvest Capital Credit Corporation Common Stock

Retrieved on: 
Wednesday, March 27, 2024
Order, Justice Center, ALL, Lis pendens, TIME, Prejudice, Class, Episcopal conference, THIS, HCAP, Calendar, Documentation, Internet, CLASS, Settlement, COMMON, Stipulation, HARVEST, Plaintiff, Address, Judgement, Hearing, Insurance

The purpose of this notice (the "Summary Notice") is to inform you of: (i) the class action lawsuit captioned In re Harvest Capital Credit Corporation Stockholder Litigation, pending in the Court of Chancery of the State of Delaware (the "Court") with Civil Action Number 2021-0164-JTL (the "Action"); (ii) the proposed settlement of this Action (the "Settlement") between Plaintiffs and Defendants; and (iii) the hearing to be held by the Court in connection with the proposed Settlement.

Key Points: 
  • The purpose of this notice (the "Summary Notice") is to inform you of: (i) the class action lawsuit captioned In re Harvest Capital Credit Corporation Stockholder Litigation, pending in the Court of Chancery of the State of Delaware (the "Court") with Civil Action Number 2021-0164-JTL (the "Action"); (ii) the proposed settlement of this Action (the "Settlement") between Plaintiffs and Defendants; and (iii) the hearing to be held by the Court in connection with the proposed Settlement.
  • If you have not received a detailed Notice of Pendency of Stockholder Class Action and Proposed Settlement, Settlement Hearing, and Right to Appear ("Notice"), you may obtain copies by writing to Harvest Capital Credit Corporation Stockholder Litigation, c/o Claims Administrator, P.O.
  • Box 4620, Portland, OR 97208-4620, 1-855-604-1813, or on the Internet at www.rg2claims.com/hcap.html .
  • No.

Early Registration Opens for 2024 International Space Station Research and Development Conference in Boston

Retrieved on: 
Thursday, March 21, 2024
Research, Conference, Government, Education, Abstract (summary), American Astronautical Society, Student, Abstract, NASA, Mathematics, Episcopal conference, STEM, Engineering

BOSTON, March 21, 2024 /PRNewswire/ -- This July, the 13th annual International Space Station Research and Development Conference (ISSRDC) returns to Boston, where leaders from the commercial sector, U.S. government agencies, and academic communities will assemble to highlight innovations and opportunities through our nation's orbiting outpost.

Key Points: 
  • BOSTON, March 21, 2024 /PRNewswire/ -- This July, the 13th annual International Space Station Research and Development Conference (ISSRDC) returns to Boston, where leaders from the commercial sector, U.S. government agencies, and academic communities will assemble to highlight innovations and opportunities through our nation's orbiting outpost.
  • ISSRDC will take place July 30-August 1, 2024, at the Marriott Copley Place in Boston.
  • Early registration is now open until May 24, 2024.
  • ISSRDC 2024 is the only conference dedicated to showcasing how the space station continues to provide a valuable platform for research and technology development that benefits humanity and enables a robust and sustainable market in low Earth orbit.